An industry-sponsored indirect treatment comparison suggesting tirzepatide 10 and 15 mg achieve greater weight, BMI and HbA1c reduction than semaglutide 2.4 mg in type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
Browsing: Metabolism
Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
A phase 1 first-in-human study of the oral GLP-1 receptor agonist ECC5004/AZD5004 in healthy volunteers and T2DM patients found it well tolerated with early dose-dependent glucose and weight signals. PICO summary and expert commentary.
Summary: In adults with obesity, exposure to GLP-1 receptor agonists and bariatric surgery significantly increased policy support for obesity treatments…
An oral GLP-1 receptor agonist lowered HbA1c and body weight in phase 2 but was halted early after transaminase elevations ended its development. PICO summary and expert commentary.
Two small crossover trials in adults with type 1 diabetes found neither protein source nor carbohydrate glycaemic index significantly altered postprandial glucose. PICO summary and expert commentary.
A 253-adult randomized trial found that 25% calorie restriction produced consistent enteropancreatic hormone shifts across diet patterns, and that larger shifts were associated with more weight regain afterwards. PICO summary and expert commentary.
A 56-week randomized, double-blind, placebo-controlled trial of liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass. PICO summary and expert commentary.
A manufacturer-sponsored randomized trial of a low-glycemic-index/slow-digesting carbohydrate product in obese pregnant women found no effect on the primary glycemic outcomes. PICO summary and expert commentary.
A first-in-human phase I trial of the NPY2 receptor agonist BI 1820237, alone or with low-dose liraglutide, in 95 men with overweight or obesity, reporting safety, tolerability, and additive effects on gastric emptying. PICO summary and expert commentary.
A small randomized trial finds baseline IL-1β in mononuclear cells predicts the degree of MASLD improvement after weight loss in obesity with prediabetes or early type 2 diabetes. PICO summary and expert commentary.